Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.30 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30997845 | 1.00 | PRCP (0.35) | PRCPKLKB1RXRAGRIN1GRIN2B | |
| SCHEMBL24737693 | 0.87 | KLKB1 (0.32) | PRCPKLKB1RXRAGRIN1GRIN2B | |
| SCHEMBL30997821 | 0.85 | KLKB1 (0.39) | KLKB1MEN1KMT2AMETTL3 | |
| SCHEMBL29302902 | 0.85 | KLKB1 (0.39) | KLKB1MEN1KMT2AMETTL3 | |
| SCHEMBL29879411 | 0.85 | MEN1 (0.33) | KLKB1MEN1KMT2A | |
| SCHEMBL29304492 | 0.85 | MEN1 (0.33) | KLKB1MEN1KMT2A | |
| SCHEMBL24737541 | 0.85 | MEN1 (0.34) | KLKB1MEN1KMT2A | |
| SCHEMBL29879124 | 0.85 | MEN1 (0.34) | KLKB1MEN1KMT2A | |
| SCHEMBL24738283 | 0.84 | KLKB1 (0.33) | KLKB1MEN1KMT2A | |
| SCHEMBL29880037 | 0.84 | KLKB1 (0.33) | KLKB1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | PRCP 243/4885KLKB1 1/4885RXRA 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.